KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2025)

Royalty Pharma's Cash & Current Investments history spans 7 years, with the latest figure at $637.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 35.43% year-over-year to $637.5 million; the TTM value through Dec 2025 reached $637.5 million, down 35.43%, while the annual FY2025 figure was $637.5 million, 35.43% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $637.5 million at Royalty Pharma, down from $955.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.5 billion in Q2 2022 and bottomed at $495.3 million in Q4 2023.
  • The 5-year median for Cash & Current Investments is $1.2 billion (2021), against an average of $1.3 billion.
  • The largest annual shift saw Cash & Current Investments soared 976.21% in 2021 before it crashed 71.07% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $1.6 billion in 2021, then grew by 6.53% to $1.7 billion in 2022, then plummeted by 71.07% to $495.3 million in 2023, then skyrocketed by 99.31% to $987.2 million in 2024, then crashed by 35.43% to $637.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Cash & Current Investments are $637.5 million (Q4 2025), $955.0 million (Q3 2025), and $645.1 million (Q2 2025).